Leflunomide Tablet, Film Coated
Product Images NDC 50090-7537

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 50090-7537). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 01)

Chemical structure of leflunomide showing its molecular arrangement with a trifluoromethyl-substituted aromatic ring connected to an amide-linked oxazole ring.*

FDA Label Image

Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 02)

Chemical structure diagram labeled as A77 1726 (teriflunomide), showing the molecular structure related to the active ingredient leflunomide.*

FDA Label Image

Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 03)

A bar chart titled '% ACR 20 Responder at Endpoint' displaying response percentages across three clinical trials comparing leflunomide, methotrexate, placebo, and sulfasalazine. The x-axis represents different drugs tested in Trials 1, 2, and 3 of varying durations, and the y-axis shows percentage values ranging from -20 to 70 percent.*

FDA Label Image

Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 04)

Line graph titled 'Trial 1 ACR Responders Over Time' showing the percentage of responders on the y-axis and time in months on the x-axis (0 to 12). It compares response rates for PL (placebo), MTX (methotrexate), and LEF (leflunomide) over 12 months, with LEF consistently showing higher response rates than PL and MTX.*

FDA Label Image

Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 05)

A bar graph titled 'Change in Sharp Score' illustrating progression values across three trials of different durations (12 months, 6 months, 12 months). The x-axis shows treatments labeled L (leflunomide), M (methotrexate), S (sulfasalazine), and P (placebo). The y-axis measures progression with values ranging from -10 to 8, showing differences in effect among the treatments in each trial.*

FDA Label Image

Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 06)

A bar chart titled "Change in Functional Ability Measure" showing improvement values for different trials and treatments. The chart compares Leflunomide (L) with Methotrexate (M), Placebo (P), and Sulfasalazine (S) over three trials with durations of 6 and 12 months. Values indicate changes measured by HAQ Disability Index for each treatment group.*

FDA Label Image

Label Image (Lbl500907537)

The packaging label for Leflunomide 20 mg film-coated tablets by A-S Medication Solutions. It includes the product's NDC (50090-7537-0), lot and product numbers, storage instructions to keep at 68 to 77 degrees Fahrenheit and to protect from light, and the package count of 30 tablets. The label also references a dosage package insert and displays the distributor's address in Libertyville, IL.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.